Frontiers in Psychiatry (Nov 2019)

Vortioxetine for Cognitive Enhancement in Major Depression: From Animal Models to Clinical Research

  • Djamila Bennabi,
  • Emmanuel Haffen,
  • Vincent Van Waes

DOI
https://doi.org/10.3389/fpsyt.2019.00771
Journal volume & issue
Vol. 10

Abstract

Read online

Objectives: Vortioxetine has already shown its efficacy in the acute and long-term treatment of major depressive disorder (MDD) and its potential interest in the prevention of relapse. The aim of this study was to review the current status of knowledge regarding its cognitive effects.Methods: We conducted a review of key data obtained from preclinical behavioral models and clinical trials in MDD focusing on vortioxetine-induced cognitive changes.Results: In animals, acute and chronic administration of vortioxetine improves performance on objective measures that cover a broad range of cognitive domains. In human, vortioxetine appears to be a useful treatment option in MDD patients with cognitive dysfunction.Conclusion: Vortioxetine constitutes a promising treatment for treatment of cognitive impairment in MDD, but its place in the therapeutic armamentarium still needs to be determined.

Keywords